Madi Madiyalakan, Ph.D.
OncoQuest Chief Executive Officer
Dr. Madiyalakan is the CEO of OncoQuest and also the CEO of Quest PharmaTech since August 2006; and Director since July 2004. He was one of the founders of SonoLight Pharmaceuticals Corp. (served as its CEO and Director), CanBiocin Inc. (served as President, CEO and Director) and AltaRex Corp. (served as Vice-President, Planning and Chief Scientific Officer). Between 1987 and 1995 Dr. Madiyalakan served in various senior positions at Biomira Inc. Dr. Madiyalakan holds a Masters (Chemistry) and Ph.D. (Biochemistry) and a Certificate in Management Development. In addition, he has over 25 years of academic and industrial research experience on an international basis. He has published extensively and been an inventor of several patents.
OncoQuest Chief Financial Officer and Senior Vice President
Mr. Awadalla has spent almost 30 years in healthcare investment banking at Merrill Lynch, UBS, and serving as Head of Healthcare M&A at Robertson Stephens and Wells Fargo and Head of Healthcare Investment Banking at Unterberg Towbin. Most recently and for the past 6 years, he served as Managing Director at National Securities. He has advised on over $15 billion of financing and M&A transactions in the healthcare sector. He received his MBA in Finance and MA in International Studies from the Wharton School and the University of Pennsylvania, respectively and his BA from Columbia University.
Thomas Woo, M.Sc.
Vice President of Product Development
As the Vice President of Product Development, Mr. Woo is focusing on process, formulation and clinical development for Quest's products. Mr. Woo has been involved in successful clinical trial applications for more than six drug candidates during his tenure at Cytovax Biotechnologies Inc., AltaRex Corp., Biomira Research Inc., and Biomira Inc. Mr. Woo holds a Bachelor of Science degree in Pharmacy and a Master of Science degree in Pharmaceutical Sciences from the University of Alberta.
Chris Nicodemus, M.D.
Senior Advisor to OncoQuest
Dr. Nicodemus is Founder, President and Chief Scientific Officer of AIT Strategies. He served as Chairman and Chief Scientific Officer of Advanced Immune Therapeutics, Inc. from 2008-2012. Dr. Nicodemus received undergraduate training at Harvard College and received his MD degree from Upstate Medical University in Syracuse, NY. He trained in Internal Medicine and completed a Research and Clinical fellowship in the laboratory of K Frank Austen, Department of Rheumatology and Clinical Immunology at Brigham and Women's Hospital, Harvard Medical School, Boston. He held various research and clinical appointments at Harvard while pursuing a career in biotechnology. He has held executive positions at Pfizer, ImmuLogic, Diatide, AltaRex, United Therapeutics and Advanced Immune Therapeutics, Inc. He is a member of Alpha Omega Alpha and a fellow of the American College of Physicians.